A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, placebo-controlled, parallel group study of EpiCept™ NP-1
Topical Cream (amitriptyline 4%/ketamine 2%) in approximately 200 patients with pain in the
lower extremities due to diabetic nerve pain.
Phase:
Phase 2
Details
Lead Sponsor:
EpiCept Corporation
Treatments:
Amitriptyline Amitriptyline, perphenazine drug combination Ketamine